Molecularly engineered BODIPY photosensitizers combined with immunotherapeutic strategies show potential for cancer treatment

Photo by ThisisEngineering / Unsplash

Frontiers in Medicine Published June 3, 2026 Medically reviewed June 3, 2026 DOI ↗ By Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development

Key Takeaway

Consider molecularly engineered BODIPY photosensitizers combined with immunotherapeutic strategies for cancer treatment

This narrative review examines the potential of molecularly engineered BODIPY photosensitizers combined with immunotherapeutic strategies for cancer treatment. The scope of the discussion centers on overcoming the limitations of conventional BODIPY dyes, which include poor water solubility, shallow tissue penetration, oxygen dependence, and insufficient single-modality efficacy. The authors explore secondary outcomes such as reactive oxygen species generation, photothermal conversion, tumor targeting, microenvironment remodeling, and synergistic antitumor effects. These engineered agents aim to address the shortcomings of traditional approaches in this field. The review does not report specific adverse events, tolerability, or discontinuation rates. Furthermore, details regarding the study population, sample size, setting, and follow-up duration were not reported. The authors highlight that the current understanding relies on the synthesis of existing concepts rather than new trial data. Consequently, the clinical application of these strategies remains theoretical until further validation is provided in rigorous studies. The review serves as a conceptual overview rather than a summary of completed clinical trials.

Study Details

Study typeSystematic review

EvidenceLevel 1

PublishedJun 2026

View Original Abstract ↓

BODIPY-based photosensitizers have attracted great interest in cancer phototherapy and immunotherapy due to their tunable structures, excellent photostability, and high molar extinction coefficients. However, conventional BODIPY dyes have inherent limitations, such as poor water solubility, shallow tissue penetration, oxygen dependence, and insufficient single-modality efficacy. To address these, recent studies have used molecular engineering (ring fusion, electronic modulation, supramolecular assembly, metal coordination) to enhance reactive oxygen species generation and photothermal conversion. Smart delivery systems with microenvironment responsiveness further enable tumor targeting and microenvironment remodeling. Importantly, BODIPY-mediated phototherapy combined with immunotherapeutic strategies (immune checkpoint blockade, pyroptosis/cuproptosis induction, cGAS-STING activation, etc.) achieves synergistic antitumor effects, transforming localized tumor ablation into systemic immunity. This review summarizes recent progress in molecularly engineered BODIPY photosensitizers, from molecular optimization and smart delivery to immune synergy, and discusses current challenges and future directions to promote their clinical translation.